I came across this work by Tzani et al (Nature Communications | (2024) 15:8605 on presence of host cell microproteins in commercially available formulated biologics. Seems like they are being considered as new class of impurity? Are these independent of classic HCPs that are normally controlled during process development. I am curious to hear from the community on their experience with these microproteins.
------------------------------
Vibha Jawa
Chief Scientific Officer
Epivax
Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
------------------------------